A UK-wide motor neurone disease research network has secured a further £5 million commitment for a second phase of work, with plans to bring more centres into the search for better treatments.
The five-year funding commitment to the UK Motor Neuron Disease Research Institute comes from the MND Association, My Name’5 Doddie Foundation and medical research organisation LifeArc. It is intended to strengthen collaboration between researchers, expand the collection of biological samples and support the development and testing of potential treatments.
The MND Association is contributing £2.2 million as part of the £5 million total. The funding is for research and its supporting infrastructure; it is not an announcement that a new treatment has been shown to work.
Building a wider research network
The institute brings together research centres working on motor neurone disease, or MND, across the UK. Its first phase involved King’s College London, University College London and the universities of Oxford, Liverpool, Sheffield and Edinburgh.
The next phase is intended to add institutions across the country, including major sites involved in the EXPERTS-ALS clinical trial. The aim is to increase the reach of the network and make it easier for more people living with MND to take part in research. Being near a participating centre does not necessarily mean that someone will be eligible for a particular study.
The institute is co-directed by professors Ammar Al-Chalabi and Christopher McDermott, and its leadership includes people living with MND. The network’s work spans understanding the disease, identifying possible drugs and testing treatments in clinical trials.
From samples to potential treatments
During its first phase, the collaboration coordinated national efforts to collect samples, developed a collection of laboratory cell models and screened more than 550 potential drugs. Screening a substance is an early research step: it does not establish that the substance is safe or effective for patients.
The planned expansion of biosampling could give researchers more material with which to investigate the condition. Biological samples can be used to study disease processes and examine differences between people. Shared approaches to collecting and using them can also help teams compare findings across centres, subject to appropriate permissions and safeguards.
Laboratory models offer another way to study possible mechanisms of disease. They allow researchers to investigate questions in controlled conditions, but a finding in cells is not the same as proof that a treatment will benefit a person. Potential therapies still need careful testing, including clinical trials where appropriate.
Research participation can take different forms. The institute’s existing programmes include an MND register and a telehealth research platform designed to allow people to contribute remotely. These are examples of work already under way, not separately announced allocations from the new commitment.
Why the research matters
MND affects motor neurones, the nerve cells that help control muscles. The condition can affect movement, speech, swallowing and breathing, although symptoms and the speed at which they change vary between people.
There is currently no cure. Treatments and specialist support can help with symptoms and daily life, and a medicine called riluzole can help slow progression for people with amyotrophic lateral sclerosis, the most common type of MND. Individual care depends on a person’s circumstances and needs.
Testing possible treatments is important because an approach that looks promising in a laboratory may not produce the same result in people. Clinical trials assess questions such as safety and effectiveness, and an experimental treatment may turn out to be no better than an existing option or may cause unexpected effects.
Campaign roots
The network grew from the United2EndMND campaign, launched by people affected by the condition in 2021 to press for greater research investment. An earlier partnership brought researchers, clinicians, charities and people living with MND together before becoming the institute.
The new five-year commitment is separate from the UK government’s earlier £50 million pledge for MND research. By supporting shared facilities and wider participation, the next phase aims to give researchers a stronger platform for their work. Its eventual value will depend on the research carried out and the evidence that emerges, rather than on the funding announcement alone.